Browse by Attribute
Browse by Column

Drug for chronic hepatitis B to begin mass production in Qingdao facility

2016/04/15

A pharmaceutical drug made in China and claimed to be a cure for the chronic hepatitis B virus recently finished clinical trials and is expected to start mass-production this year at a facility in Qungdao that is due to be completed by August. As a national major new drug development project, it has cost Beijing-based Genova Biotech 15 years and a total investment of over 1 billion yuan ($154.7 million). The drug, Novaferon, will be priced 50-percent cheaper than imported drugs with the same function, according to the company.


Source: HEALTH.PEOPLE.COM.CN




Click Ranking

People watch


Chen Jun: Accumulation and Sublimation
It is lucky for Chen Jun to began his career in the IP industry 14 years ago when the first group of IP managers for businesses appeared on the stage in China and he has been in the industry.

Foxconn in Those Years
It was this “Whampoa Military Academy” for IP that educated China’s first batch of corporate IP management personnel. Many of these engineers left Foxconn in the years since.

more
2018 ANNUAL INVENTORY OF THE The Progress and Challenges of Copyright Industry in China Interview with Cheng Lingjun, Intellectual Property Director of Joyoung Co., Ltd. Interview with Chen Lingpei, General Manager of IP Division, Autodesk, Inc. (Greater China) Constant Accumulation Makes theLatecomers Surpass—Interview with Huang Lu, Director of IP Center of Humanwell Healthcare (Gr Between Lawyer and Manager —Interview with Xia Feng, the Chief IP Counsel of Greater China & Asia-Pacific, Honeywell (China) Patent Prosecution Highway and its Application Overview of EU copyright levy system – in the case of mobile phones